However, since early disease-modifying treatments for Alzheimer’s disease are likely to target amyloid aggregation—although tau-focused therapies are also in development—markers of cortical pathology such as amyloidosis will become central in assessing eligibility for new treatments. Here, MAPT is linked to amyloidosis.